Navigation Links
R. Lindholm Named to Crux Biomedical Board
Date:3/14/2011

MENLO PARK, Calif., March 14, 2011 /PRNewswire/ -- Crux Biomedical, developer of an advanced implantable vena cava filter (IVCF) to prevent pulmonary embolisms, announced the appointment of Randy Lindholm to its Board of Directors. Mr. Lindholm is a widely respected advisor to the medical device field. He was previously Chairman and CEO of Vidamed,  a maker of minimally invasive medical devices to treat benign prostate hyperplasia until it was acquired by Medtronic in 2002.  Prior to Vidamed, Randy held senior positions at Nellcor Puritan Bennett and GE Medical Systems. " I am excited to join Crux Biomedical. They are well positioned to take advantage of the current interest in a better performing retrievable IVC filter," stated Mr. Lindholm. He currently serves as director of publically held Omnicell (MLCL), Barrx Medical, Tibion Bionic Technologies, Estech and Novasys Medical.

"We are very pleased to have Randy's operating experience at Crux," states Mel Schatz, CEO of Crux Biomedical. He continued, "Randy has assisted numerous firms in securing venture backed funding."  Crux Biomedical is currently enrolling patients in its pivotal IDE study in the United States and several sites internationally. It expects to complete the U.S. study in 2011 and launch internationally  later this year.

Crux Biomedical was founded in 2004 by Thomas Fogarty, M.D., to target the development of an advanced implantable inferior vena cava filter (IVCF) to prevent the occurrence of potentially fatal pulmonary embolisms. Although routinely used in the United States, currently cleared IVC filters are associated with a variety of complications. "We recognized current IVC filters did not meet the needs of clinicians and designed a filter that provided better retrievability," stated Tom Fogarty, M.D.

Each year in the United States approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur. Pulmonary embolisms are recognized as the most frequent cause of death among hospitalized patients.

Crux Biomedical is located in Menlo Park, California and is funded by Alloy Ventures and Emergent Medical Partners.


'/>"/>
SOURCE Crux Biomedical
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
2. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
3. Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps
4. Dawn Phillips Named as Vice President, Business Development for Catastrophic & Home Health Services
5. Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomens Association
6. Dynatronics Named Contract Supplier to Amerinets 50,000 Members
7. R&J Public Relations Named Agency of Record for Aerocrine, Inc.
8. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
9. Kevin Banion Named CEO of Progressive Medical, Inc.
10. Webmedx Named Best in KLAS and Ranked #1 Transcription Services Vendor for Second Year in a Row
11. Elektas MOSAIQ Oncology Information System Named Category Leader in 2010 Top 20 Best in KLAS Awards Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
Breaking Medicine News(10 mins):